Lack of Associations of the COMT Val158Met Polymorphism with Risk of Endometrial and Ovarian Cancer: a Pooled Analysis of Case-control Studies

Liu, Jin-Xin; Luo, Rong-Cheng; Li, Rong; Li, Xia; Guo, Yu-Wu; Ding, Da-Peng; Chen, Yi-Zhi

추천

검색

자료유형: 학술저널

저자정보: Liu, Jin-Xin (Department of Oncology, Longgang District Central Hospital of ShenZhen) Luo, Rong-Cheng (Department of Oncology, TCM-Integrated Hospital, Southern Medical University) Li, Rong (Department of Oncology, Nanfang Hospital) Li, Xia (Department of Oncology, Longgang District Central Hospital of ShenZhen) Guo, Yu-Wu (Department of Oncology, Longgang District Central Hospital of ShenZhen) Ding, Da-Peng (Institute of Genetic Engineering, Southern Medical University) Chen, Yi-Zhi (Department of Health Records, Longgang District Central Hospital of ShenZhen)

저널정보: 아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제15권 제15호

발행연도: 2014.1

수록면: 6,181 - 6,186 (6page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

This meta-analysis was conducted to examine whether the genotype status of Val158Met polymorphism in catechol-O-methyltransferase (COMT) is associated with endometrial and ovarian cancer risk. Eligible studies were identified by searching several databases for relevant reports published before January 1, 2014. Pooled odds ratios (ORs) were appropriately derived from fixed-effects or random-effects models. In total, 15 studies (1,293 cases and 2,647 controls for ovarian cancer and 2,174 cases and 2,699 controls for endometrial cancer) were included in the present meta-analysis. When all studies were pooled into the meta-analysis, there was no evidence for significant association between COMT Val158Met polymorphism and ovarian cancer risk (Val/Met versus Val/Val: OR=0.91, 95% CI=0.76-1.08; Met/Met versus Val/Val: OR=0.90, 95% CI=0.73-1.10; dominant model: OR=0.90, 95% CI=0.77-1.06; recessive model: OR=0.95, 95% CI=0.80-1.13). Similarly, no associations were found in all comparisons for endometrial cancer (Val/Met versus Val/Val: OR 0.97, 95% CI=0.77-1.21; Met/Met versus Val/Val: OR=1.02, 95% CI=0.73-1.42; dominant model: OR=0.98, 95% CI=0.77-1.25; recessive model: OR=1.02, 95% CI=0.87-1.20). In the subgroup analyses by source of control and ethnicity, no significant associations were found in any subgroup of population. This meta-analysis strongly suggests that COMT Val158Met polymorphism is not associated with increased endometrial and ovarian cancer risk.

#COMT #endometrial cancer #ovarian cancer #risk #meta-analysis

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요